Sorafenib-loaded polymeric micelles as passive targeting therapeutic agents for hepatocellular carcinoma therapy

Nanomedicine (Lond). 2018 May;13(9):1009-1023. doi: 10.2217/nnm-2018-0046. Epub 2018 Apr 9.

Abstract

Aim: The clinical application of sorafenib is limited because of its hydrophobicity, low bioavailability and unsatisfying treatment effect. Therefore, sorafenib-loaded PEG-poly (ε-caprolactone) micelles (SF micelles) were fabricated for sorafenib delivery.

Materials & methods: In vitro assays investigated the solubility, dispersity, stability, cytotoxicity and uptake capacity of SF micelles. In vivo biodistribution and therapeutic effects were studied using HepG2-Luc tumor-bearing mice.

Results: SF micelles had a regular spherical structure with good water solubility. In vivo imaging results showed PEG-poly (ε-caprolactone) micelles could elevate the sorafenib concentration in tumor tissues. Meanwhile, SF micelles exhibited higher tumor growth inhibition in vivo.

Conclusion: SF micelles might be a potential drug delivery system, which could enhance the therapeutic effects of sorafenib.

Keywords: drug delivery; hepatocellular carcinoma; micelles; sorafenib; therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carcinoma, Hepatocellular / drug therapy*
  • Cell Line, Tumor
  • Drug Delivery Systems / methods
  • Hep G2 Cells
  • Humans
  • Liver Neoplasms / drug therapy*
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Micelles*
  • Polyethylene Glycols / chemistry*
  • Polymers / administration & dosage
  • Polymers / chemistry*
  • Sorafenib / chemistry*
  • Sorafenib / therapeutic use

Substances

  • Micelles
  • Polymers
  • Polyethylene Glycols
  • Sorafenib